Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

December 14, 2024

Study Completion Date

December 23, 2024

Conditions
Symptomatic Knee Osteoarthritis
Interventions
DRUG

DFV890

DFV890

DRUG

Placebo

Placebo

Trial Locations (31)

1027

Novartis Investigative Site, Budapest

4000

Novartis Investigative Site, San Miguel de Tucumán

6044

Novartis Investigative Site, Kecskemét

8200

Novartis Investigative Site, Veszprém

10787

Novartis Investigative Site, Berlin

15006

Novartis Investigative Site, A Coruña

18209

Novartis Investigative Site, Bad Doberan

22143

Novartis Investigative Site, Hamburg

22415

Novartis Investigative Site, Hamburg

30501

Ctr for Adv Research and Education, Gainesville

32789

Conquest Research, Winter Park

33324

IRIS Research and Development, Plantation

41010

Novartis Investigative Site, Seville

60611

Northwestern University, Chicago

66250

Novartis Investigative Site, Brno

80917

Skylight Health Res Inc Color Spr, Colorado Springs

85015

ARENSIA Explor Med Res Clinic, Phoenix

91501

Novartis Investigative Site, Nové Mesto nad Váhom

92020

TriWest Reserach Associates, El Cajon

92101

Novartis Investigative Site, Piešťany

400006

Novartis Investigative Site, Cluj-Napoca

C1181ACH

Novartis Investigative Site, CABA

T4000CBC

Novartis Investigative Site, San Miguel de Tucumán

741 01

Novartis Investigative Site, Nový Jičín

150 06

Novartis Investigative Site, Prague

686 01

Novartis Investigative Site, Uherské Hradiště

04107

Novartis Investigative Site, Leipzig

H-3526

Novartis Investigative Site, Miskolc

011658

Novartis Investigative Site, Bucharest

08208

Novartis Investigative Site, Sabadell

08003

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY